<DOC>
	<DOCNO>NCT02428985</DOCNO>
	<brief_summary>The primary objective study collect post-marketing information Riociguat safety.Thus , information adverse event ( AEs ) adverse drug reaction ( ADRs ) occur within first 12 month follow 6 -year observation , start Riociguat treatment routine clinical practice collect . The secondary objective collect information Riociguat effectiveness , 6-Minute Walking Distance ( 6MWD ) Test . Since assume Riociguat long-term use , information Pulmonary Arterial Hypertension ( PAH ) clinical worsening also survey year .</brief_summary>
	<brief_title>Prospective , Non-interventional , Multi-center , Post-authorization Safety Study Riociguat Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>This local , prospective , non-interventional , multi-center study include patient treat Riociguat PAH . A total 600 patient ( valid safety analysis ) plan include 4 year . This study perform `` all-case investigation '' therefore ; patient receive Riociguat treatment PAH need register , principle . The treatment perform base product label Japan . The standard observation period last 12 month start Riociguat treatment . Safety effectiveness evaluate 3rd 12th month treatment . In addition , extension observation period carry long Riociguat treatment continue 6 year . The purpose collect information safety effectiveness , adverse event clinical worsen PAH , year . Combining standard observation extension observation period patient could follow 7 year . When Riociguat treatment terminate , observation patient end . The investigator record data patient , define protocol , use Electronic Data Capture ( EDC ) system . The duration study approximately 8 year PAH indication approval .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Patients treat Riociguat PAH</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Riociguat</keyword>
	<keyword>Adempas</keyword>
	<keyword>soluble guanylate cyclase ( sGC ) stimulator</keyword>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>Japan</keyword>
	<keyword>Post-marketing surveillance</keyword>
</DOC>